Abstract
Several tumor cell systems have been developed for investigating the cytotoxic activity of different substances. The Ehrlich ascytic tumor (EAT) has been studied extensively and used to increase our comprehension of immunotherapy (Yamamoto and Naraparaju. Cancer Res 57:2187–2192, 1997). In this study, we evaluated the ability of an enzymatic method to assess cytotoxic tumor activity in vitro. To prepare cytotoxic cells, lymphoid cells isolated from the lymph nodes of C57BL/6 mice were activated with interleukin‐2 (IL‐2). The cytotoxic activity to EAT cells was assessed by an enzymatic test using lactate dehydrogenase (LDH), an enzyme widely distributed in mammalian tissues which, in the presence of NAD/NADH, converts lactate to pyruvate. IL‐2 treatment of lymph node cells induced a greater percentage of lysis (75.47%) than effector cells that were not treated with IL‐2 (42.38%). This suggests that IL‐2 directly activates effector cells and not tumor cells. The results demonstrate that the LDH release‐measurement method can be utilized to assay cytotoxic cell‐mediated activity in which murine tumor cells act as the target. Levels of IL‐2 appear to have a direct correlation to cellular immunity and treatment with these substances may strengthen immune function and decrease the pace of disease development. J. Clin. Lab. Anal. 18:27–30, 2004. © 2004 Wiley‐Liss, Inc.
Keywords: LDH, IL‐2, tumor cells, cytotoxicity
REFERENCES
- 1. Sule NS, Nerurkar RP, Kamath S. Interleukin‐2 as a therapeutic agent. J Assoc Physicians India 2001;49:897–900. [PubMed] [Google Scholar]
- 2. Jicha DL, Mulle JJ, Rosenberg SA. Interleukin 7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy. J Exp Med 1991;174:1511–1515. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Kurslock R, Talpaz M, Gutterman JU. Interferons‐clinical applications In: DeVita VT, Hellman SM, Rosenberg SA, editors. Biological therapy of cancer. Philadelphia: JB Lippincott; 1991, p 344–345. [Google Scholar]
- 4. Brunda MJ. Interleukin 12. J Leukoc Biol 1994;55:280–288. [DOI] [PubMed] [Google Scholar]
- 5. Robertson AA, Clark DA. Immunology of the reproductive tract and pregnancy. The Immunologist 1999;7:38–39. [Google Scholar]
- 6. Guirguis LM, Yang JC, White DE, et al. Safety and efficacy of high‐dose interleukin‐2 therapy in patients with brain metastases. J Immunother 2002;25:82–87. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Scheibenbogen C, Sun Y, Keilholz U, et al. Identification of known and novel immunogenic T‐cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding IL‐2‐based treatment. Int J Cancer 2002;98:409–414. [DOI] [PubMed] [Google Scholar]
- 8. De Groot CJ, Cadee JA, Koten JW, Hennink Den Otter W. Therapeutic efficacy of IL‐2‐loaded hydrogels in a mouse tumor model. Int J Cancer 2002;98:134–140. [DOI] [PubMed] [Google Scholar]
- 9. Allen M, Millet P, Dawes E, Rushton N. Lactate dehydrogenase activity as a rapid and sensitive test for the quantification of cell numbers in vitro. Clin Mater 1994;16:189–194. [DOI] [PubMed] [Google Scholar]
- 10. Decker T, Lohmann‐Matthes ML. A quick and simple method for the quantification of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods 1998;115:61–69. [DOI] [PubMed] [Google Scholar]
- 11. Henry JB, editor. Clinical diagnosis and management by laboratory methods. Philadelphia: W.B. Saunders Company; 1996. pp 877–912. [Google Scholar]
- 12. Wang E, Phan GQ, Marincola FM. T‐cell‐directed cancer vaccines: the melanoma model. Exper Opin Biol Ther 2001; 1(2 1(2):277–290. [DOI] [PubMed] [Google Scholar]
- 13. Brunner KT, Mauel J, Cerottini JC, Chapuis B. Quantitative assay of the lytic action of immune lymphoid cells on 51‐Cr‐labelled allogeneic target cells in vitro: inhibition by issoantibody and by drugs. Immunology 1968;14:181–196. [PMC free article] [PubMed] [Google Scholar]